Brought to you by 
Cerevel created to work on several CNS assets from Pfizer
Oct 2018
Executive Summary
Concurrent with being spun-off from Pfizer Inc. and Bain Capital, Boston-based Cerevel Therapeutics LLC has in-licensed several neuroscience assets from the Big Pharma.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Equity
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cerevel created to work on several CNS assets from Pfizer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice